BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Selle K, Fletcher JR, Tuson H, Schmitt DS, McMillan L, Vridhambal GS, Rivera AJ, Montgomery SA, Fortier LC, Barrangou R, Theriot CM, Ousterout DG. In Vivo Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials. mBio 2020;11:e00019-20. [PMID: 32156803 DOI: 10.1128/mBio.00019-20] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Gibb B, Hyman P, Schneider CL. The Many Applications of Engineered Bacteriophages-An Overview. Pharmaceuticals (Basel) 2021;14:634. [PMID: 34208847 DOI: 10.3390/ph14070634] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Sáez Moreno D, Visram Z, Mutti M, Restrepo-Córdoba M, Hartmann S, Kremers AI, Tišáková L, Schertler S, Wittmann J, Kalali B, Monecke S, Ehricht R, Resch G, Corsini L. ε2-Phages Are Naturally Bred and Have a Vastly Improved Host Range in Staphylococcus aureus over Wild Type Phages. Pharmaceuticals (Basel) 2021;14:325. [PMID: 33918287 DOI: 10.3390/ph14040325] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Au TY, Assavarittirong C. Combating antimicrobial resistance: an evidence-based overview of bacteriophage therapy. Postgrad Med J 2022:postgradmedj-2022-141546. [PMID: 35379752 DOI: 10.1136/postgradmedj-2022-141546] [Reference Citation Analysis]
4 Cruz KCP, Enekegho LO, Stuart DT. Bioengineered Probiotics: Synthetic Biology Can Provide Live Cell Therapeutics for the Treatment of Foodborne Diseases. Front Bioeng Biotechnol 2022;10:890479. [DOI: 10.3389/fbioe.2022.890479] [Reference Citation Analysis]
5 Marongiu L, Burkard M, Venturelli S, Allgayer H. Dietary Modulation of Bacteriophages as an Additional Player in Inflammation and Cancer. Cancers (Basel) 2021;13:2036. [PMID: 33922485 DOI: 10.3390/cancers13092036] [Reference Citation Analysis]
6 Dowdell AS, Colgan SP. Metabolic Host-Microbiota Interactions in Autophagy and the Pathogenesis of Inflammatory Bowel Disease (IBD). Pharmaceuticals (Basel) 2021;14:708. [PMID: 34451805 DOI: 10.3390/ph14080708] [Reference Citation Analysis]
7 Wang Y, Sheng J, Chai J, Zhu C, Li X, Yang W, Cui R, Ge T. Filamentous Bacteriophage-A Powerful Carrier for Glioma Therapy. Front Immunol 2021;12:729336. [PMID: 34566987 DOI: 10.3389/fimmu.2021.729336] [Reference Citation Analysis]
8 Hashemi Shahraki A, Mirsaeidi M. Phage Therapy for Mycobacterium Abscessus and Strategies to Improve Outcomes. Microorganisms 2021;9:596. [PMID: 33799414 DOI: 10.3390/microorganisms9030596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Park EM, Chelvanambi M, Bhutiani N, Kroemer G, Zitvogel L, Wargo JA. Targeting the gut and tumor microbiota in cancer. Nat Med 2022;28:690-703. [PMID: 35440726 DOI: 10.1038/s41591-022-01779-2] [Reference Citation Analysis]
10 Zhang Y, Saint Fleur A, Feng H. The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota. Gut Microbes 2022;14:2052698. [PMID: 35319337 DOI: 10.1080/19490976.2022.2052698] [Reference Citation Analysis]
11 Bhat P, Garibyan L. The potential of CRISPR guided therapies in the dermatology clinic. JID Innovations 2022. [DOI: 10.1016/j.xjidi.2022.100103] [Reference Citation Analysis]
12 Kreis V, Soutourina O. Clostridioides difficile - phage relationship the RNA way. Curr Opin Microbiol 2021;66:1-10. [PMID: 34922145 DOI: 10.1016/j.mib.2021.11.012] [Reference Citation Analysis]
13 Wu Y, Battalapalli D, Hakeem MJ, Selamneni V, Zhang P, Draz MS, Ruan Z. Engineered CRISPR-Cas systems for the detection and control of antibiotic-resistant infections. J Nanobiotechnology 2021;19:401. [PMID: 34863214 DOI: 10.1186/s12951-021-01132-8] [Reference Citation Analysis]
14 Łobocka M, Dąbrowska K, Górski A. Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future. BioDrugs 2021;35:255-80. [PMID: 33881767 DOI: 10.1007/s40259-021-00480-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
15 Nale JY, Clokie MR. Preclinical data and safety assessment of phage therapy in humans. Curr Opin Biotechnol 2021;68:310-7. [PMID: 33862490 DOI: 10.1016/j.copbio.2021.03.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Palacios Araya D, Palmer KL, Duerkop BA. CRISPR-based antimicrobials to obstruct antibiotic-resistant and pathogenic bacteria. PLoS Pathog 2021;17:e1009672. [PMID: 34237097 DOI: 10.1371/journal.ppat.1009672] [Reference Citation Analysis]
17 Phothichaisri W, Chankhamhaengdecha S, Janvilisri T, Nuadthaisong J, Phetruen T, Fagan RP, Chanarat S. Potential Role of the Host-Derived Cell-Wall Binding Domain of Endolysin CD16/50L as a Molecular Anchor in Preservation of Uninfected Clostridioides difficile for New Rounds of Phage Infection. Microbiol Spectr 2022;:e0236121. [PMID: 35377223 DOI: 10.1128/spectrum.02361-21] [Reference Citation Analysis]
18 Peng H, Rossetto D, Mansy SS, Jordan MC, Roos KP, Chen IA. Treatment of Wound Infections in a Mouse Model Using Zn2+-Releasing Phage Bound to Gold Nanorods. ACS Nano 2022. [PMID: 35239330 DOI: 10.1021/acsnano.2c00048] [Reference Citation Analysis]
19 Lam KN, Spanogiannopoulos P, Soto-Perez P, Alexander M, Nalley MJ, Bisanz JE, Nayak RR, Weakley AM, Yu FB, Turnbaugh PJ. Phage-delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome. Cell Rep 2021;37:109930. [PMID: 34731631 DOI: 10.1016/j.celrep.2021.109930] [Reference Citation Analysis]
20 Parsons C, Brown P, Kathariou S. Use of Bacteriophage Amended with CRISPR-Cas Systems to Combat Antimicrobial Resistance in the Bacterial Foodborne Pathogen Listeria monocytogenes. Antibiotics (Basel) 2021;10:308. [PMID: 33802904 DOI: 10.3390/antibiotics10030308] [Reference Citation Analysis]
21 Javaudin F, Latour C, Debarbieux L, Lamy-Besnier Q. Intestinal Bacteriophage Therapy: Looking for Optimal Efficacy. Clin Microbiol Rev 2021;:e0013621. [PMID: 34668734 DOI: 10.1128/CMR.00136-21] [Reference Citation Analysis]
22 Phanchana M, Harnvoravongchai P, Wongkuna S, Phetruen T, Phothichaisri W, Panturat S, Pipatthana M, Charoensutthivarakul S, Chankhamhaengdecha S, Janvilisri T. Frontiers in antibiotic alternatives for Clostridioides difficile infection. World J Gastroenterol 2021; 27(42): 7210-7232 [PMID: 34876784 DOI: 10.3748/wjg.v27.i42.7210] [Reference Citation Analysis]
23 Zhan Y, Li XP, Yin JY. COVID-19 one year later: a retrospect of CRISPR-Cas system in combating COVID-19. Int J Biol Sci 2021;17:2080-8. [PMID: 34131407 DOI: 10.7150/ijbs.60655] [Reference Citation Analysis]
24 Coleman ME, Dietert RR, North DW, Stephenson MM. Enhancing Human Superorganism Ecosystem Resilience by Holistically ‘Managing Our Microbes’. Applied Microbiology 2021;1:471-97. [DOI: 10.3390/applmicrobiol1030031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Meile S, Du J, Dunne M, Kilcher S, Loessner MJ. Engineering therapeutic phages for enhanced antibacterial efficacy. Curr Opin Virol 2021;52:182-91. [PMID: 34952266 DOI: 10.1016/j.coviro.2021.12.003] [Reference Citation Analysis]
26 Yeh TK, Jean SS, Lee YL, Lu MC, Ko WC, Lin HJ, Liu PY, Hsueh PR. Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy. Int J Antimicrob Agents 2021;:106475. [PMID: 34767917 DOI: 10.1016/j.ijantimicag.2021.106475] [Reference Citation Analysis]
27 Duan C, Cao H, Zhang LH, Xu Z. Harnessing the CRISPR-Cas Systems to Combat Antimicrobial Resistance. Front Microbiol 2021;12:716064. [PMID: 34489905 DOI: 10.3389/fmicb.2021.716064] [Reference Citation Analysis]
28 Loose M, Sáez Moreno D, Mutti M, Hitzenhammer E, Visram Z, Dippel D, Schertler S, Tišáková LP, Wittmann J, Corsini L, Wagenlehner F. Natural Bred ε2-Phages Have an Improved Host Range and Virulence against Uropathogenic Escherichia coli over Their Ancestor Phages. Antibiotics (Basel) 2021;10:1337. [PMID: 34827275 DOI: 10.3390/antibiotics10111337] [Reference Citation Analysis]
29 Peng W, Zeng F, Wu Z, Jin Z, Li W, Zhu M, Wang Q, Tong Y, Chen L, Bai Q. Isolation and genomic analysis of temperate phage 5W targeting multidrug-resistant Acinetobacter baumannii. Arch Microbiol 2022;204. [DOI: 10.1007/s00203-021-02618-7] [Reference Citation Analysis]
30 Azam AH, Tan XE, Veeranarayanan S, Kiga K, Cui L. Bacteriophage Technology and Modern Medicine. Antibiotics (Basel) 2021;10:999. [PMID: 34439049 DOI: 10.3390/antibiotics10080999] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 León Y, Faherty CS. Bacteriophages against enteropathogens: rediscovery and refinement of novel antimicrobial therapeutics. Curr Opin Infect Dis 2021;34:491-9. [PMID: 34524200 DOI: 10.1097/QCO.0000000000000772] [Reference Citation Analysis]